Wegovy 4.8 mg: is this the right dose for you?

Why you might have seen 4.8 mg mentioned

The number 4.8 mg crops up in a few places: older international discussions, some consumer forums, and occasionally the maths people do when converting between weekly and daily figures. None of those routes lead to a licensed UK dose. The published Wegovy schedule (set out in the prescribing information held on the Electronic Medicines Compendium (eMC)) moves in specific steps that were chosen through the STEP clinical trial programme to balance tolerability and efficacy. If you're wondering whether 4.8 mg of Wegovy is something you could take, the short answer is that it isn't among the licensed strengths.

That matters because the steps aren't arbitrary. Each rung on the schedule gives your system roughly four weeks to adapt before the dose rises again. Skipping to an unlicensed figure, or trying to source a non-standard strength, would mean working outside the evidence base entirely. The decision about which licensed dose you're on, and when you move, sits with your prescriber, full stop.

If you arrived here because you're curious about a specific step in the schedule, our full Wegovy dose overview walks through every licensed stage and what to expect at each one.

The dose you'd actually be on around that point in treatment

If the 4.8 mg figure has come up in the context of your own treatment timeline, the closest licensed doses on either side are 1.7 mg and 2.4 mg. Most people reach 1.7 mg around week 12, and if you want detail on what that step involves, our page on Wegovy 1 mg and how that part of the schedule works gives useful context on the earlier stages leading up to it. That 2.4 mg step is where the bulk of the STEP 1 trial evidence sits: around 15% average body-weight reduction over 68 weeks was reported among adults without type 2 diabetes, as published in the New England Journal of Medicine's STEP 1 paper.

Some people do stay longer at 1.7 mg if their prescriber judges it the right call, perhaps because side effects need more time to settle, or because weight loss is already progressing well. That isn't a failure; it's the schedule working as designed. What your prescriber won't do is invent a dose between steps. The strengths that exist are the ones that exist.

For context on what comes next after 2.4 mg, the page on 5 mg Wegovy covers the upper end of the schedule, including the newer 7.2 mg maintenance option.

Whether staying at a lower dose or moving up is the right call

This is the real decision most people are actually facing when they search around the 4.8 mg mark: should I push for a higher dose, or is where I am enough? A few factors your prescriber considers:

Weight-loss response. NICE guidance on semaglutide notes that if less than 5% weight loss has occurred after six months at the maintenance dose, continuing should be reviewed. That benchmark is a clinical signal, not a personal judgement. The NICE technology appraisal TA875 sets this out for NHS contexts, and private prescribers follow the same clinical logic.

Side-effect picture. Gastrointestinal effects (nausea especially) tend to be most noticeable in the first couple of weeks after each dose increase, then ease for most people. If they haven't eased, your prescriber may hold the current dose rather than advance. That's the right call, not a setback.

The 7.2 mg option. The MHRA approved a dedicated single-dose 7.2 mg pen in April 2026 for adults with a BMI of 30 or above. Trials reported around 20.7% average weight loss at this dose over 72 weeks, which narrows the gap with tirzepatide results considerably. If you're thinking about whether a higher dose might be relevant for you, that conversation starts with a prescriber, not a search engine. Our guide to Wegovy's full strength range has more background on how the 7.2 mg dose works in practice.

One practical note: if you're planning to start or restart treatment, order timing can matter more than people expect. Ordering before a bank holiday or during a busy holiday week means dispatch timelines may shift slightly, worth factoring in if you want continuity at a particular point in your schedule.

Getting the right dose through a proper clinical assessment

A prescriber's dose decision isn't just about BMI and a chart. They're looking at how you've responded so far, any medications you're already taking, your weight-related health conditions, and whether the schedule is working for your body rather than against it. There's no shortcut that replicates that. Buying from a seller who can't provide that oversight (one offering medicines without a prescription or any clinical review) is the wrong trade-off, however appealing the price looks. The MHRA has been clear on the risks of counterfeit pens, and the short version is: a genuine supply chain and a real prescriber aren't optional extras.

At nume, a GPhC-registered prescriber reads your consultation personally on the same day. If you want to understand which dose of Wegovy is appropriate for you, and whether you meet the eligibility criteria, you can start a free consultation today. Our Wegovy overview page covers the full picture if you want more background first, and our clinical team is there if you have questions about the process.